CHMP has issued a positive opinion supporting Laboratoires Pierre’ approval for Javlor. Also, it is recommending to grant marketing authorisation as monotherapy in metastatic treatment of bladder cancer.
Miraculins has finalized a research collaboration agreement with Diagnostic Technologies. The company has also announced the execution of a cooperation and project funding agreement with DTL and CIIRDF
GlaxoSmithKline (GSK) announced that the Commercial Court in Dublin, Ireland, has ruled in patent litigation regarding GSK’s Seretide, an inhaled respiratory treatment for asthma and COPD. Justice Charleton
Aclasta (zoledronic acid 5 mg) has been approved in the European Union (EU) to treat men and postmenopausal women with osteoporosis. It is caused by long-term use of
CHMP of the European Medicines Agency (EMEA) has issued a positive opinion about Boehringer Ingelheim’s Mirapexin/Sifrol (pramipexole). It has recommended the approval of once daily formulation for Mirapexin/Sifrol
Intercell has announced that the US Centers for Disease Control and Prevention (CDC’) Advisory Committee on Immunization Practices (ACIP) voted to update its previous recommendations and include IXIARO,
Protalix has initiated home care treatment program for patients enrolled in the phase-III extension trial of plant-cell expressed recombinant glucocerebrosidase (prGCD). The phase-III extension trial is a follow-on
Sandoz has received marketing authorization for the Japanese biosimilar, recombinant human growth hormone somatropin. The Ministry of Health, Labor and Wealth announced the approval on June 22, based
OraSure has provided update regarding the status of its application for FDA approval of an OraQuick Hepatitis C (HCV) test, and its clinical program for an OraQuick HIV-1/2
A subsidiary of Ligand has entered into an exclusive license agreement with ParinGenix. Under the agreement, ParinGenix was granted exclusive license rights to three issued US patents relating
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.